Skip to main content
Clinical Trials/CTRI/2009/091/000251
CTRI/2009/091/000251
Completed
Phase 2

Clinical trial to assess the efficacy and safety of TNK-TPA in Acute Ischemic Stroke

Gennova Biopharmaceuticals Limited Pune0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Gennova Biopharmaceuticals Limited Pune
Enrollment
50
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Gennova Biopharmaceuticals Limited Pune

Eligibility Criteria

Inclusion Criteria

  • 1\. Ischemic stroke with serious measurable deficit on National Institute of Health Stroke Scale (NIHSS)
  • 2\. Treatment within 3 hours of stroke onset
  • 3\. Age 18 to 75 years
  • 4\. Patient or legally acceptable representative willing to give informed consent before study procedure

Exclusion Criteria

  • 1\. Minor stroke symptoms or major symptoms rapidly improving
  • 2\. Intracranial hemorrhage on pretreatment head computerised tomography (CT) scan
  • 3\. Clinical presentation suggesting subarachnoid haemorrhage
  • 4\. Pregnancy
  • 5\. Known bleeding diathesis and/or platelet count \< 100 000 mm3
  • 6\. Patient taking oral anticoagulants.
  • 7\. Patients who have received heparin within 48 hours
  • 8\. Major surgery or serious trauma within 14 days; serious head trauma within 3 months
  • 9\. Gastrointestinal or urinary tract hemorrhage within 21 days
  • 10\. Arterial puncture at a noncompressible site or lumbar puncture within 7 days

Outcomes

Primary Outcomes

Not specified

Similar Trials